Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S ADR (NY: NVO )

106.13 UNCHANGED
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
65 66 Next >
Bring On The Competition In Obesity Drugs: Novo Nordisk CEO Optimistic About Prolonged Patient Adherence to Obesity Drug Wegovy
Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S (NYSE: NVO), shared insights during the JPMorgan Healthcare conference, highlighting Wegovy's efficacy for weight loss, indicating that patients are... 
Via Benzinga
3 Simple Tricks That Every Investor Should Use (but Most Don't)
Having a few tricks up your sleeve can increase your returns over time. 
Via The Motley Fool
Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles
Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning 
Via Benzinga
Can Simply Good Foods ride the GLP-1 weight loss trend in 2024?
Simply Good Foods may be ready to breakout as the GLP-1 medication weight-loss trend is driving up sales for its Atkins and Quest Nutrition branded products 
Via MarketBeat
Could Novo Nordisk Stock Help You Retire a Millionaire?
This company is steadily gaining in value, and its growth runway is quite long, too. 
Via The Motley Fool
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Ozempic Users Might Experience Caloric Intake Rise Post-Discontinuation: Survey
Novo Nordisk's Wegovy has been linked to greater weight loss with prolonged use, with 40% of patients still using the drug a year later. This adherence rate is three times higher than other... 
Via Benzinga
Dexcom's Recent 66% Run Continues With A Breakout On Bullish Fourth-Quarter Sales
Dexcom beat fourth-quarter sales expectations and issued stronger-than-usual annual guidance. 
Via Investor's Business Daily
Wegovy and Ozempic Maker Novo Nordisk Shares Data From Phase 3 Diabetes Study Of Semaglutide/Insulin Containing Candidate
Novo Nordisk A/S (NYSE: NVO) announced topli 
Via Benzinga
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took 
Via MarketBeat
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
Via Investor Brand Network
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
Exposures Product Safety
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges. 
Via MarketBeat
Topics ETFs
Nvidia, Spotify Lead Five Stocks Near Buy Points
Nvidia could make some noise with its CES presentation Monday. 
Via Investor's Business Daily
Why Is WeightWatchers (WW) Stock Down 5% Today?
Investors in Weight Watchers and WW stock are seeing more declines today, as investors price in the impact of a rival's new site. 
Via InvestorPlace
Stock Market Skids To Start 2024 As Tesla, Apple Stumble, Mobileye Crashes: Weekly Review
Tesla, Apple and Mobileye were key losers. 
Via Investor's Business Daily
Novo Nordisk's Ozempic And Wegovy Helps Lose Weight, Not One's Mind: US Study Find No Increased Suicidal Thoughts Risk
On Friday, a comprehensive U.S. 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. 
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Global Giants: 3 Multinational Corporations to Outperform in 2024
Participate in the growth of the global economy and consumption through these leading global stocks for 2024. 
Via InvestorPlace
Topics Economy
Exposures Economy
Why Novo Nordisk Stock Crushed the Market Today
The company just boosted its research and development efforts. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Eli Lilly Launches Website To Help Patients With Home Delivery Options For Weight Loss Medicines
Eli Lilly announced a new website allowing patients to get a weight loss drug prescription through a telehealth provider, with disease management resources, home delivery of medicines. 
Via Benzinga
Eli Lilly Beefs Up Its Weight-Loss Marketing Efforts With New Direct-To-Consumer Site
Eli Lilly will connect patients with doctors, support and direct-to-home delivery of specific medicines. 
Via Investor's Business Daily
Famed Obesity Drug Maker Novo Nordisk Inks Collaborations For Cardiometabolic Diseases
Novo Nordisk A/S (NYSE: NVO), Omega Therapeutics Inc (NASDAQ: OMGA), and Cellarity Inc. 
Via Benzinga
Is the January Effect reliable indicator for yearly performance?
The January Effect refers to January’s market return as predictive of the full year. But is January's performance truly an indicator of how the year may go? 
Via MarketBeat
Topics ETFs
Novo Nordisk, The Weight-Loss Kingpin, Inks Two New Obesity Deals
Shares of one new partner nearly doubled after Novo Nordisk pledged to pay up to $532 million. 
Via Investor's Business Daily
The Best Stocks to Invest $1,000 in Right Now
It's not too late to get in on these market beaters. 
Via The Motley Fool
Why Is Omega Therapeutics (OMGA) Stock Up 111% Today?
Omega Therapeutics stock is rising higher on Thursday as investors in OMGA react to a search collaboration agreement with Novo Nordisk. 
Via InvestorPlace
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.